{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:28:09Z","timestamp":1790666889020,"version":"4.1.0"},"reference-count":148,"publisher":"Bentham Science Publishers Ltd.","issue":"6","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["406041\/2018-0"],"award-info":[{"award-number":["406041\/2018-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["301037\/2016-7"],"award-info":[{"award-number":["301037\/2016-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa de Minas Gerais","doi-asserted-by":"publisher","award":["CDS-APQ-02541- 17"],"award-info":[{"award-number":["CDS-APQ-02541- 17"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PPL"],"published-print":{"date-parts":[[2020,6,9]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Cerebrovascular Diseases (CVD) comprise a wide spectrum of disorders, all sharing an\nacquired or inherited alteration of the cerebral vasculature. CVD have been associated with\nimportant changes in systemic and tissue Renin-Angiotensin System (RAS). The aim of this review\nwas to summarize and to discuss recent findings related to the modulation of RAS components in\nCVD. The role of RAS axes is more extensively studied in experimentally induced stroke. By\nmeans of AT1 receptors in the brain, Ang II hampers cerebral blood flow and causes tissue\nischemia, inflammation, oxidative stress, cell damage and apoptosis. On the other hand, Ang-(1-7)\nby stimulating Mas receptor promotes angiogenesis in brain tissue, decreases oxidative stress,\nneuroinflammation, and improves cognition, cerebral blood flow, neuronal survival, learning and\nmemory. In regard to clinical studies, treatment with Angiotensin Converting Enzyme (ACE)\ninhibitors and AT1 receptor antagonists exerts preventive and therapeutic effects on stroke. Besides\nstroke, studies support a similar role of RAS molecules also in traumatic brain injury and cerebral\naneurysm. The literature supports a beneficial role for the alternative RAS axis in CVD. Further\nstudies are necessary to investigate the therapeutic potential of ACE2 activators and\/or Mas\nreceptor agonists in patients with CVD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929866527666191218091823","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T12:11:23Z","timestamp":1576671083000},"page":"463-475","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Renin-Angiotensin System and the Cerebrovascular Diseases: Experimental and Clinical Evidence"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3678-118X","authenticated-orcid":true,"given":"Lucas M.","family":"Kangussu","sequence":"first","affiliation":[{"name":"Department of Morphology \u2013 Biological Science Institute, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-7895","authenticated-orcid":true,"given":"Lucas Alexandre Santos","family":"Marzano","sequence":"additional","affiliation":[{"name":"Interdisciplinary Laboratory of Medical Investigation - Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9196-6956","authenticated-orcid":true,"given":"C\u00e1ssio Ferraz","family":"Souza","sequence":"additional","affiliation":[{"name":"Interdisciplinary Laboratory of Medical Investigation - Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-6867","authenticated-orcid":true,"given":"Carolina Couy","family":"Dantas","sequence":"additional","affiliation":[{"name":"Interdisciplinary Laboratory of Medical Investigation - Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-7924","authenticated-orcid":true,"given":"Aline Silva","family":"Miranda","sequence":"additional","affiliation":[{"name":"Interdisciplinary Laboratory of Medical Investigation - Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-3882","authenticated-orcid":true,"given":"Ana Cristina","family":"Sim\u00f5es e Silva","sequence":"additional","affiliation":[{"name":"Interdisciplinary Laboratory of Medical Investigation - Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/bc.bc_11_17","volume":"3","author":"Chandra A.","year":"2017","unstructured":"Chandra A.; Stone C.R.; Li W.A.; Geng X.; Ding Y.; The cerebral circulation and cerebrovascular disease II: Pathogenesis of cerebrovascular disease. Brain Circ 2017,3(2),57-65","journal-title":"Brain Circ"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJMra1201534","volume":"369","author":"Murray C.J.","year":"2013","unstructured":"Murray C.J.; Lopez A.D.; Measuring the global burden of disease. N Engl J Med 2013,369(5),448-457","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000441083","volume":"45","author":"Roth G.A.","year":"2015","unstructured":"Roth G.A.; Johnson C.O.; Nguyen G.; Naghavi M.; Feigin V.L.; Murray C.J.; Forouzanfar M.H.; Vos T.; Methods for estimating the global burden of cerebrovascular diseases. Neuroepidemiology 2015,45(3),146-151","journal-title":"Neuroepidemiology"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1097\/01.hjh.0000220416.07235.37","volume":"24","author":"Th\u00f6ne-Reineke C.","year":"2006","unstructured":"Th\u00f6ne-Reineke C.; Steckelings U.M.; Unger T.; Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl 2006,24(1)(Suppl.),S115-S121","journal-title":"J Hypertens Suppl"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1161\/01.STR.31.10.2478","volume":"31","author":"Nishimura Y.","year":"2000","unstructured":"Nishimura Y.; Ito T.; Saavedra J.M.; Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000,31(10),2478-2486","journal-title":"Stroke"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1042\/CS20130324","volume":"126","author":"Regenhardt R.W.","year":"2014","unstructured":"Regenhardt R.W.; Bennion D.M.; Sumners C.; Cerebroprotective action of angiotensin peptides in stroke. Clin Sci (Lond) 2014,126(3),195-205","journal-title":"Clin Sci (Lond)"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1152\/physrev.00036.2005","volume":"86","author":"Paul M.","year":"2006","unstructured":"Paul M.; Poyan Mehr A.; Kreutz R.; Physiology of local renin-angiotensin systems. Physiol Rev 2006,86(3),747-803","journal-title":"Physiol Rev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","volume":"264","author":"Fyhrquist F.","year":"2008","unstructured":"Fyhrquist F.; Saijonmaa O.; Renin-angiotensin system revisited. J Intern Med 2008,264(3),224-236","journal-title":"J Intern Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1210\/en.2003-0150","volume":"144","author":"Lavoie J.L.","year":"2003","unstructured":"Lavoie J.L.; Sigmund C.D.; Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system. Endocrinology 2003,144(6),2179-2183","journal-title":"Endocrinology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"33238","DOI":"10.1074\/jbc.M002615200","volume":"275","author":"Tipnis S.R.","year":"2000","unstructured":"Tipnis S.R.; Hooper N.M.; Hyde R.; Karran E.; Christie G.; Turner A.J.; A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000,275(43),33238-33243","journal-title":"J Biol Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","volume":"87","author":"Donoghue M.","year":"2000","unstructured":"Donoghue M.; Hsieh F.; Baronas E.; Godbout K.; Gosselin M.; Stagliano N.; Donovan M.; Woolf B.; Robison K.; Jeyaseelan R.; Breitbart R.E.; Acton S.; A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000,87(5),E1-E9","journal-title":"Circ Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"8258","DOI":"10.1073\/pnas.1432869100","volume":"100","author":"Santos R.A.","year":"2003","unstructured":"Santos R.A.; Simoes e Silva A.C.; Maric C.; Silva D.M.; Machado R.P.; de Buhr I.; Heringer-Walther S.; Pinheiro S.V.; Lopes M.T.; Bader M.; Mendes E.P.; Lemos V.S.; Campagnole-Santos M.J.; Schultheiss H.P.; Speth R.; Walther T.; Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003,100(14),8258-8263","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0014-5793(94)01292-9","volume":"357","author":"Metzger R.","year":"1995","unstructured":"Metzger R.; Bader M.; Ludwig T.; Berberich C.; Bunnemann B.; Ganten D.; Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett 1995,357(1),27-32","journal-title":"FEBS Lett"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/01.ATV.0000253889.09765.5f","volume":"27","author":"Jankowski V.","year":"2007","unstructured":"Jankowski V.; Vanholder R.; van der Giet M.; T\u00f6lle M.; Karadogan S.; Gobom J.; Furkert J.; Oksche A.; Krause E.; Tran T.N.; Tepel M.; Schuchardt M.; Schl\u00fcter H.; Wiedon A.; Beyermann M.; Bader M.; Todiras M.; Zidek W.; Jankowski J.; Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 2007,27(2),297-302","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","volume":"112","author":"Lautner R.Q.","year":"2013","unstructured":"Lautner R.Q.; Villela D.C.; Fraga-Silva R.A.; Silva N.; Verano-Braga T.; Costa-Fraga F.; Jankowski J.; Jankowski V.; Sousa F.; Alzamora A.; Soares E.; Barbosa C.; Kjeldsen F.; Oliveira A.; Braga J.; Savergnini S.; Maia G.; Peluso A.B.; Passos-Silva D.; Ferreira A.; Alves F.; Martins A.; Raizada M.; Paula R.; Motta-Santos D.; Klempin F.; Pimenta A.; Alenina N.; Sinisterra R.; Bader M.; Campagnole-Santos M.J.; Santos R.A.; Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 2013,112(8),1104-1111","journal-title":"Circ Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"H958","DOI":"10.1152\/ajpheart.00723.2018","volume":"316","author":"Santos R.A.S.","year":"2019","unstructured":"Santos R.A.S.; Oudit G.Y.; Verano-Braga T.; Canta G.; Steckelings U.M.; Bader M.; The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol 2019,316(5),H958-H970","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.2174\/0929867325666180226102358","volume":"25","author":"Rocha N.P.","year":"2018","unstructured":"Rocha N.P.; Simoes E Silva A.C.; Prestes T.R.R.; Feracin V.; Machado C.A.; Ferreira R.N.; Teixeira A.L.; de Miranda A.S.; Silva, A.C.; Prestes, T.R.R.; Feracin, V.; RAS in the central nervous system: Potential role in neuropsychiatric disorders. Curr Med Chem 2018,25(28),3333-3352","journal-title":"Curr Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0149-7634(94)90034-5","volume":"18","author":"Wright J.W.","year":"1994","unstructured":"Wright J.W.; Harding J.W.; Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Biobehav Rev 1994,18(1),21-53","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030876","volume":"19","author":"Jackson L.","year":"2018","unstructured":"Jackson L.; Eldahshan W.; Fagan S.C.; Ergul A.; Within the brain: The renin angiotensin system. Int J Mol Sci 2018,19(3)","journal-title":"Int J Mol Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2174\/0929866524666170822120258","volume":"24","author":"Almeida-Santos A.F.","year":"2017","unstructured":"Almeida-Santos A.F.; Kangussu L.M.; Campagnole-Santos M.J.; The renin-angiotensin system and the neurodegenerative diseases: A brief review. Protein Pept Lett 2017,24(9),841-853","journal-title":"Protein Pept Lett"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1592\/phco.25.4.531.61022","volume":"25","author":"Epstein B.J.","year":"2005","unstructured":"Epstein B.J.; Gums J.G.; Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers. Pharmacotherapy 2005,25(4),531-539","journal-title":"Pharmacotherapy"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"S277","DOI":"10.1007\/s10072-008-0963-9","volume":"29","author":"Marcheselli S.","year":"2008","unstructured":"Marcheselli S.; Micieli G.; Renin-angiotensin system and stroke. Neurol Sci 2008,29(Suppl. 2),S277-S278","journal-title":"Neurol Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1524-6175.2007.06602.x","volume":"9","author":"Chrysant S.G.","year":"2007","unstructured":"Chrysant S.G.; The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications. J Clin Hypertens (Greenwich) 2007,9(6),454-459","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00109-008-0331-5","volume":"86","author":"Phillips M.I.","year":"2008","unstructured":"Phillips M.I.; de Oliveira E.M.; Brain renin angiotensin in disease. J Mol Med (Berl) 2008,86(6),715-722","journal-title":"J Mol Med (Berl)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1042\/CS20150350","volume":"130","author":"Fouda A.Y.","year":"2016","unstructured":"Fouda A.Y.; Artham S.; El-Remessy A.B.; Fagan S.C.; Renin-angiotensin system as a potential therapeutic target in stroke and retinopathy: experimental and clinical evidence. Clin Sci (Lond) 2016,130(4),221-238","journal-title":"Clin Sci (Lond)"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1212\/01.WNL.0000130360.21618.D0","volume":"63","author":"Sokol S.I.","year":"2004","unstructured":"Sokol S.I.; Portnay E.L.; Curtis J.P.; Nelson M.A.; Hebert P.R.; Setaro J.F.; Foody J.M.; Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004,63(2),208-213","journal-title":"Neurology"},{"key":"ref=27","doi-asserted-by":"publisher","DOI":"10.4081\/ni.2011.e12","volume":"3","author":"Ravenni R.","year":"2011","unstructured":"Ravenni R.; Jabre J.F.; Casiglia E.; Mazza A.; Primary stroke prevention and hypertension treatment: which is the first-line strategy? Neurol Int 2011,3(2)","journal-title":"Neurol Int"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/B:MEBR.0000043966.46964.e6","volume":"19","author":"Mergenthaler P.","year":"2004","unstructured":"Mergenthaler P.; Dirnagl U.; Meisel A.; Pathophysiology of stroke: lessons from animal models. Metab Brain Dis 2004,19(3-4),151-167","journal-title":"Metab Brain Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1161\/01.STR.12.6.723","volume":"12","author":"Astrup J.","year":"1981","unstructured":"Astrup J.; Siesj\u00f6 B.K.; Symon L.; Thresholds in cerebral ischemia - the ischemic penumbra. Stroke 1981,12(6),723-725","journal-title":"Stroke"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1161\/01.STR.0000048846.09677.62","volume":"34","author":"Ginsberg M.D.","year":"2003","unstructured":"Ginsberg M.D.; Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. Stroke 2003,34(1),214-223","journal-title":"Stroke"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1097\/00001756-199411000-00018","volume":"5","author":"N\u00e4veri L.","year":"1994","unstructured":"N\u00e4veri L.; Str\u00f6mberg C.; Saavedra J.M.; Angiotensin II AT1 receptor mediated contraction of the perfused rat cerebral artery. Neuroreport 1994,5(17),2278-2280","journal-title":"Neuroreport"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/01.STR.0000121642.53822.58","volume":"35","author":"Stenman E.","year":"2004","unstructured":"Stenman E.; Edvinsson L.; Cerebral ischemia enhances vascular angiotensin AT1 receptor-mediated contraction in rats. Stroke 2004,35(4),970-974","journal-title":"Stroke"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/sj.jcbfm.9600204","volume":"26","author":"Faraci F.M.","year":"2006","unstructured":"Faraci F.M.; Lamping K.G.; Modrick M.L.; Ryan M.J.; Sigmund C.D.; Didion S.P.; Cerebral vascular effects of angiotensin II: new insights from genetic models. J Cereb Blood Flow Metab 2006,26(4),449-455","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2165\/00129784-200505040-00004","volume":"5","author":"Wilms H.","year":"2005","unstructured":"Wilms H.; Rosenstiel P.; Unger T.; Deuschl G.; Lucius R.; Neuroprotection with angiotensin receptor antagonists: a review of the evidence and potential mechanisms. Am J Cardiovasc Drugs 2005,5(4),245-253","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/01.STR.30.11.2391","volume":"30","author":"Dai W.J.","year":"1999","unstructured":"Dai W.J.; Funk A.; Herdegen T.; Unger T.; Culman J.; Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999,30(11),2391-2398","journal-title":"Stroke"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/00004647-200404000-00012","volume":"24","author":"Engelhorn T.","year":"2004","unstructured":"Engelhorn T.; Goerike S.; Doerfler A.; Okorn C.; Forsting M.; Heusch G.; Schulz R.; The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 2004,24(4),467-474","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/01.hjh.0000254376.80864.d3","volume":"25","author":"Brdon J.","year":"2007","unstructured":"Brdon J.; Kaiser S.; Hagemann F.; Zhao Y.; Culman J.; Gohlke P.; Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke. J Hypertens 2007,25(1),187-196","journal-title":"J Hypertens"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1447-0594.2012.00900.x","volume":"13","author":"Mogi M.","year":"2013","unstructured":"Mogi M.; Horiuchi M.; Effect of angiotensin II type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases. Geriatr Gerontol Int 2013,13(1),13-18","journal-title":"Geriatr Gerontol Int"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S0006-8993(99)01577-2","volume":"835","author":"Hosomi N.","year":"1999","unstructured":"Hosomi N.; Mizushige K.; Kitadai M.; Ohyama H.; Ichihara S.I.; Takahashi T.; Matsuo H.; Induced hypertension treatment to improve cerebral ischemic injury after transient forebrain ischemia. Brain Res 1999,835(2),188-196","journal-title":"Brain Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.neuroscience.2005.03.054","volume":"134","author":"Hosomi N.","year":"2005","unstructured":"Hosomi N.; Nishiyama A.; Ban C.R.; Naya T.; Takahashi T.; Kohno M.; Koziol J.A.; Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 2005,134(1),225-231","journal-title":"Neuroscience"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1161\/01.RES.0000148637.85595.c5","volume":"95","author":"Kazama K.","year":"2004","unstructured":"Kazama K.; Anrather J.; Zhou P.; Girouard H.; Frys K.; Milner T.A.; Iadecola C.; Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res 2004,95(10),1019-1026","journal-title":"Circ Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/STROKEAHA.108.531707","volume":"40","author":"De Silva T.M.","year":"2009","unstructured":"De Silva T.M.; Broughton B.R.; Drummond G.R.; Sobey C.G.; Miller A.A.; Gender influences cerebral vascular responses to angiotensin II through Nox2-derived reactive oxygen species. Stroke 2009,40(4),1091-1097","journal-title":"Stroke"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.brainres.2009.06.056","volume":"1286","author":"Jackman K.A.","year":"2009","unstructured":"Jackman K.A.; Miller A.A.; Drummond G.R.; Sobey C.G.; Importance of NOX1 for angiotensin II-induced cerebrovascular superoxide production and cortical infarct volume following ischemic stroke. Brain Res 2009,1286,215-220","journal-title":"Brain Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1161\/01.RES.0000189301.10217.87","volume":"97","author":"Miller A.A.","year":"2005","unstructured":"Miller A.A.; Drummond G.R.; Schmidt H.H.; Sobey C.G.; NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res 2005,97(10),1055-1062","journal-title":"Circ Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"H1890","DOI":"10.1152\/ajpheart.00464.2003","volume":"285","author":"Kazama K.","year":"2003","unstructured":"Kazama K.; Wang G.; Frys K.; Anrather J.; Iadecola C.; Angiotensin II attenuates functional hyperemia in the mouse somatosensory cortex. Am J Physiol Heart Circ Physiol 2003,285(5),H1890-H1899","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/01.ATV.0000253885.41509.25","volume":"27","author":"Girouard H.","year":"2007","unstructured":"Girouard H.; Park L.; Anrather J.; Zhou P.; Iadecola C.; Cerebrovascular nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II. Arterioscler Thromb Vasc Biol 2007,27(2),303-309","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"H156","DOI":"10.1152\/ajpheart.01137.2007","volume":"294","author":"Girouard H.","year":"2008","unstructured":"Girouard H.; Lessard A.; Capone C.; Milner T.A.; Iadecola C.; The neurovascular dysfunction induced by angiotensin II in the mouse neocortex is sexually dimorphic. Am J Physiol Heart Circ Physiol 2008,294(1),H156-H163","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/HYPERTENSIONAHA.109.133249","volume":"54","author":"Capone C.","year":"2009","unstructured":"Capone C.; Anrather J.; Milner T.A.; Iadecola C.; Estrous cycle-dependent neurovascular dysfunction induced by angiotensin II in the mouse neocortex. Hypertension 2009,54(2),302-307","journal-title":"Hypertension"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.109.145813","volume":"55","author":"Capone C.","year":"2010","unstructured":"Capone C.; Faraco G.; Anrather J.; Zhou P.; Iadecola C.; Cyclooxygenase 1-derived prostaglandin E2 and EP1 receptors are required for the cerebrovascular dysfunction induced by angiotensin II. Hypertension 2010,55(4),911-917","journal-title":"Hypertension"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"H397","DOI":"10.1152\/ajpheart.00679.2010","volume":"300","author":"Capone C.","year":"2011","unstructured":"Capone C.; Faraco G.; Park L.; Cao X.; Davisson R.L.; Iadecola C.; The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol Heart Circ Physiol 2011,300(1),H397-H407","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3389\/fphys.2012.00484","volume":"3","author":"De Silva T.M.","year":"2013","unstructured":"De Silva T.M.; Faraci F.M.; Effects of angiotensin II on the cerebral circulation: role of oxidative stress. Front Physiol 2013,3,484","journal-title":"Front Physiol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1549-8719.2010.00060.x","volume":"17","author":"Vital S.A.","year":"2010","unstructured":"Vital S.A.; Terao S.; Nagai M.; Granger D.N.; Mechanisms underlying the cerebral microvascular responses to angiotensin II-induced hypertension. Microcirculation 2010,17(8),641-649","journal-title":"Microcirculation"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.neuroscience.2010.09.029","volume":"171","author":"Zhang M.","year":"2010","unstructured":"Zhang M.; Mao Y.; Ramirez S.H.; Tuma R.F.; Chabrashvili T.; Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience 2010,171(3),852-858","journal-title":"Neuroscience"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1161\/01.HYP.0000042427.05390.5C","volume":"41","author":"Baumbach G.L.","year":"2003","unstructured":"Baumbach G.L.; Sigmund C.D.; Faraci F.M.; Cerebral arteriolar structure in mice overexpressing human renin and angiotensinogen. Hypertension 2003,41(1),50-55","journal-title":"Hypertension"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1161\/01.CIR.90.4.2056","volume":"90","author":"Lonn E.M.","year":"1994","unstructured":"Lonn E.M.; Yusuf S.; Jha P.; Montague T.J.; Teo K.K.; Benedict C.R.; Pitt B.; Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994,90(4),2056-2069","journal-title":"Circulation"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1592\/phco.24.11.1064.36137","volume":"24","author":"Hilleman D.E.","year":"2004","unstructured":"Hilleman D.E.; Lucas B.D.; Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction? Pharmacotherapy 2004,24(8),1064-1076","journal-title":"Pharmacotherapy"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/bmj.324.7339.699","volume":"324","author":"Bosch J.","year":"2002","unstructured":"Bosch J.; Yusuf S.; Pogue J.; Sleight P.; Lonn E.; Rangoonwala B.; Davies R.; Ostergren J.; Probstfield J.; Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002,324(7339),699-702","journal-title":"BMJ"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"E28","DOI":"10.1161\/hy1101.099502","volume":"38","author":"Svensson P.","year":"2001","unstructured":"Svensson P.; de Faire U.; Sleight P.; Yusuf S.; Ostergren J.; Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001,38(6),E28-E32","journal-title":"Hypertension"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","year":"2002","unstructured":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial2002,288(23),2981-2997","journal-title":"JAMA"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM199803053381003","volume":"338","author":"Estacio R.O.","year":"1998","unstructured":"Estacio R.O.; Jeffers B.W.; Hiatt W.R.; Biggerstaff S.L.; Gifford N.; Schrier R.W.; The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998,338(10),645-652","journal-title":"N Engl J Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2337\/diacare.21.4.597","volume":"21","author":"Tatti P.","year":"1998","unstructured":"Tatti P.; Pahor M.; Byington R.P.; Di Mauro P.; Guarisco R.; Strollo G.; Strollo F.; Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998,21(4),597-603","journal-title":"Diabetes Care"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","volume":"317","year":"1998","unstructured":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ UK Prospective Diabetes Study Group1998,317(7160),713-720","journal-title":"BMJ"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"Hansson L.","year":"1999","unstructured":"Hansson L.; Lindholm L.H.; Niskanen L.; Lanke J.; Hedner T.; Niklason A.; Luomanm\u00e4ki K.; Dahl\u00f6f B.; de Faire U.; M\u00f6rlin C.; Karlberg B.E.; Wester P.O.; Bj\u00f6rck J.E.; Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999,353(9153),611-616","journal-title":"Lancet"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","volume":"354","author":"Hansson L.","year":"1999","unstructured":"Hansson L.; Lindholm L.H.; Ekbom T.; Dahl\u00f6f B.; Lanke J.; Scherst\u00e9n B.; Wester P.O.; Hedner T.; de Faire U.; Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999,354(9192),1751-1756","journal-title":"Lancet"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMoa021716","volume":"348","author":"Wing L.M.","year":"2003","unstructured":"Wing L.M.; Reid C.M.; Ryan P.; Beilin L.J.; Brown M.A.; Jennings G.L.; Johnston C.I.; McNeil J.J.; Macdonald G.J.; Marley J.E.; Morgan T.O.; West M.J.; A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003,348(7),583-592","journal-title":"N Engl J Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","year":"2001","unstructured":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet PROGRESS Collaborative Group2001,358(9287),1033-1041","journal-title":"Lancet"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.vph.2018.08.006","volume":"111","author":"Smeda J.S.","year":"2018","unstructured":"Smeda J.S.; Watson D.; Stuckless J.; Negandhi A.; Post-stroke losartan and captopril treatments arrest hemorrhagic expansion in SHRsp without lowering blood pressure. Vascul Pharmacol 2018,111,26-35","journal-title":"Vascul Pharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1161\/01.CIR.0000138848.58269.80","volume":"110","author":"Iwai M.","year":"2004","unstructured":"Iwai M.; Liu H.W.; Chen R.; Ide A.; Okamoto S.; Hata R.; Sakanaka M.; Shiuchi T.; Horiuchi M.; Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004,110(7),843-848","journal-title":"Circulation"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1097\/01.hjh.0000244952.54738.f6","volume":"24","author":"Iwai M.","year":"2006","unstructured":"Iwai M.; Chen R.; Ide A.; Iwanami J.; Tomochika H.; Tomono Y.; Mogi M.; Horiuchi M.; The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage. J Hypertens 2006,24(10),2023-2031","journal-title":"J Hypertens"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbrc.2011.04.142","volume":"409","author":"Tsukuda K.","year":"2011","unstructured":"Tsukuda K.; Mogi M.; Iwanami J.; Min L.J.; Jing F.; Oshima K.; Horiuchi M.; Irbesartan attenuates ischemic brain damage by inhibition of MCP-1\/CCR2 signaling pathway beyond AT receptor blockade. Biochem Biophys Res Commun 2011,409(2),275-279","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.neuropharm.2006.05.029","volume":"51","author":"Hamai M.","year":"2006","unstructured":"Hamai M.; Iwai M.; Ide A.; Tomochika H.; Tomono Y.; Mogi M.; Horiuchi M.; Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress. Neuropharmacology 2006,51(4),822-828","journal-title":"Neuropharmacology"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.peptides.2005.03.010","volume":"26","author":"Steckelings U.M.","year":"2005","unstructured":"Steckelings U.M.; Kaschina E.; Unger T.; The AT2 receptor--a matter of love and hate. Peptides 2005,26(8),1401-1409","journal-title":"Peptides"},{"key":"ref=73","author":"Stier C.T.","unstructured":"Stier C.T.; Adler L.A.; Levine S.; Chander P.N.;  Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats  J Hypertens Suppl, 1993, 11(3), S37-S42","journal-title":"Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats  J Hypertens Suppl, 1993, 11(3), S37-S42"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1161\/01.STR.0000163084.16505.e3","volume":"36","author":"Kim-Mitsuyama S.","year":"2005","unstructured":"Kim-Mitsuyama S.; Yamamoto E.; Tanaka T.; Zhan Y.; Izumi Y.; Izumiya Y.; Ioroi T.; Wanibuchi H.; Iwao H.; Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. Stroke 2005,36(5),1083-1088","journal-title":"Stroke"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/00004647-200405000-00008","volume":"24","author":"Lou M.","year":"2004","unstructured":"Lou M.; Blume A.; Zhao Y.; Gohlke P.; Deuschl G.; Herdegen T.; Culman J.; Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J Cereb Blood Flow Metab 2004,24(5),536-547","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1097\/00004872-200311000-00028","volume":"21","author":"Groth W.","year":"2003","unstructured":"Groth W.; Blume A.; Gohlke P.; Unger T.; Culman J.; Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 2003,21(11),2175-2182","journal-title":"J Hypertens"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1097\/00001756-200412030-00017","volume":"15","author":"Lu Q.","year":"2004","unstructured":"Lu Q.; Zhu Y.Z.; Wong P.T.; Angiotensin receptor gene expression in candesartan mediated neuroprotection. Neuroreport 2004,15(17),2643-2646","journal-title":"Neuroreport"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1096\/fj.04-2960fje","volume":"19","author":"Li J.","year":"2005","unstructured":"Li J.; Culman J.; H\u00f6rtnagl H.; Zhao Y.; Gerova N.; Timm M.; Blume A.; Zimmermann M.; Seidel K.; Dirnagl U.; Unger T.; Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005,19(6),617-619","journal-title":"FASEB J"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"Dahl\u00f6f B.","year":"2002","unstructured":"Dahl\u00f6f B.; Devereux R.B.; Kjeldsen S.E.; Julius S.; Beevers G.; de Faire U.; Fyhrquist F.; Ibsen H.; Kristiansson K.; Lederballe-Pedersen O.; Lindholm L.H.; Nieminen M.S.; Omvik P.; Oparil S.; Wedel H.; Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet LIFE Study Group2002,359(9311),995-1003","journal-title":"Lancet"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","volume":"36","author":"Schrader J.","year":"2005","unstructured":"Schrader J.; L\u00fcders S.; Kulschewski A.; Hammersen F.; Plate K.; Berger J.; Zidek W.; Dominiak P.; Diener H.C.; Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke MOSES Study Group2005,36(6),1218-1226","journal-title":"Stroke"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/S0140-6736(07)60669-2","volume":"369","author":"Mochizuki S.","year":"2007","unstructured":"Mochizuki S.; Dahl\u00f6f B.; Shimizu M.; Ikewaki K.; Yoshikawa M.; Taniguchi I.; Ohta M.; Yamada T.; Ogawa K.; Kanae K.; Kawai M.; Seki S.; Okazaki F.; Taniguchi M.; Yoshida S.; Tajima N.; Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007,369(9571),1431-1439","journal-title":"Lancet"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1093\/eurheartj\/ehp363","volume":"30","author":"Sawada T.","year":"2009","unstructured":"Sawada T.; Yamada H.; Dahl\u00f6f B.; Matsubara H.; Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009,30(20),2461-2469","journal-title":"Eur Heart J"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa060838","volume":"354","author":"Julius S.","year":"2006","unstructured":"Julius S.; Nesbitt S.D.; Egan B.M.; Weber M.A.; Michelson E.L.; Kaciroti N.; Black H.R.; Grimm R.H.; Messerli F.H.; Oparil S.; Schork M.A.; Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006,354(16),1685-1697","journal-title":"N Engl J Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1161\/STROKEAHA.107.503458","volume":"39","author":"Li J.M.","year":"2008","unstructured":"Li J.M.; Mogi M.; Iwanami J.; Min L.J.; Tsukuda K.; Sakata A.; Fujita T.; Iwai M.; Horiuchi M.; Temporary pretreatment with the angiotensin II type 1 receptor blocker, valsartan, prevents ischemic brain damage through an increase in capillary density. Stroke 2008,39(7),2029-2036","journal-title":"Stroke"},{"key":"ref=85","author":"de Gasparo M.","unstructured":"de Gasparo M.; Catt K.J.; Inagami T.; Wright J.W.; Unger T.;  International union of pharmacology  XXIII. The angiotensin II\n\treceptors. Pharmacol. Rev., 2000, 52(3), 415-472.","journal-title":"International union of pharmacology"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1096\/fj.02-1193fje","volume":"17","author":"Reinecke K.","year":"2003","unstructured":"Reinecke K.; Lucius R.; Reinecke A.; Rickert U.; Herdegen T.; Unger T.; Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J 2003,17(14),2094-2096","journal-title":"FASEB J"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1210\/me.2006-0005","volume":"21","author":"Li J.M.","year":"2007","unstructured":"Li J.M.; Mogi M.; Tsukuda K.; Tomochika H.; Iwanami J.; Min L.J.; Nahmias C.; Iwai M.; Horiuchi M.; Angiotensin II-induced neural differentiation via angiotensin II type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1. Mol Endocrinol 2007,21(2),499-511","journal-title":"Mol Endocrinol"},{"key":"ref=88","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.06.017","author":"Saavedra J.M.","unstructured":"Saavedra J.M.;  Beneficial effects of Angiotensin II receptor blockers in brain disorders  Pharmacol. Res., 2017, 125(Pt A), 91-103.","journal-title":"Beneficial effects of Angiotensin II receptor blockers in brain disorders"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1358\/dot.2004.40.9.850498","volume":"40","author":"Chrysant S.G.","year":"2004","unstructured":"Chrysant S.G.; Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today (Barc) 2004,40(9),791-801","journal-title":"Drugs Today (Barc)"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s11906-012-0257-8","volume":"14","author":"Chrysant S.G.","year":"2012","unstructured":"Chrysant S.G.; The role of angiotensin II receptors in stroke protection. Curr Hypertens Rep 2012,14(3),202-208","journal-title":"Curr Hypertens Rep"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","volume":"359","author":"Yusuf S.","year":"2008","unstructured":"Yusuf S.; Diener H.C.; Sacco R.L.; Cotton D.; Ounpuu S.; Lawton W.A.; Palesch Y.; Martin R.H.; Albers G.W.; Bath P.; Bornstein N.; Chan B.P.; Chen S.T.; Cunha L.; Dahl\u00f6f B.; De Keyser J.; Donnan G.A.; Estol C.; Gorelick P.; Gu V.; Hermansson K.; Hilbrich L.; Kaste M.; Lu C.; Machnig T.; Pais P.; Roberts R.; Skvortsova V.; Teal P.; Toni D.; VanderMaelen C.; Voigt T.; Weber M.; Yoon B.W.; Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008,359(12),1225-1237","journal-title":"N Engl J Med"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"Yusuf S.","year":"2008","unstructured":"Yusuf S.; Teo K.K.; Pogue J.; Dyal L.; Copland I.; Schumacher H.; Dagenais G.; Sleight P.; Anderson C.; Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008,358(15),1547-1559","journal-title":"N Engl J Med"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","volume":"372","author":"Yusuf S.","year":"2008","unstructured":"Yusuf S.; Teo K.; Anderson C.; Pogue J.; Dyal L.; Copland I.; Schumacher H.; Dagenais G.; Sleight P.; Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomized controlled trial. The Telmisartan Randomised Assessment Study in ACE iN tolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Lancet 2008,372(9644),1174-1183","journal-title":"Lancet"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(11)60104-9","volume":"377","author":"Sandset E.C.","year":"2011","unstructured":"Sandset E.C.; Bath P.M.; Boysen G.; Jatuzis D.; K\u00f5rv J.; L\u00fcders S.; Murray G.D.; Richter P.S.; Roine R.O.; Ter\u00e9nt A.; Thijs V.; Berge E.; The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011,377(9767),741-750","journal-title":"Lancet"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","volume":"25","author":"Turnbull F.","year":"2007","unstructured":"Turnbull F.; Neal B.; Pfeffer M.; Kostis J.; Algert C.; Woodward M.; Chalmers J.; Zanchetti A.; MacMahon S.; Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007,25(5),951-958","journal-title":"J Hypertens"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"Turnbull F.","year":"2003","unstructured":"Turnbull F.; Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003,362(9395),1527-1535","journal-title":"Lancet"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"b1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"Law M.R.","year":"2009","unstructured":"Law M.R.; Morris J.K.; Wald N.J.; Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009,338,b1665","journal-title":"BMJ"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bph.12159","volume":"169","author":"Sim\u00f5es e Silva A.C.","year":"2013","unstructured":"Sim\u00f5es e Silva A.C.; Silveira K.D.; Ferreira A.J.; Teixeira M.M.; ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 2013,169(3),477-492","journal-title":"Br J Pharmacol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11906-014-0433-0","volume":"16","author":"Etelvino G.M.","year":"2014","unstructured":"Etelvino G.M.; Peluso A.A.; Santos R.A.; New components of the renin-angiotensin system: alamandine and the MAS-related G protein-coupled receptor D. Curr Hypertens Rep 2014,16(6),433","journal-title":"Curr Hypertens Rep"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.113.01274","volume":"63","author":"Santos R.A.S.","year":"2014","unstructured":"Santos R.A.S.; Angiotensin-(1-7). Hypertension 2014,63(6),1138-1147","journal-title":"Hypertension"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"R804","DOI":"10.1152\/ajpregu.00222.2010","volume":"300","author":"Xu P.","year":"2011","unstructured":"Xu P.; Sriramula S.; Lazartigues E.; ACE2\/ANG-(1-7)\/Mas pathway in the brain: the axis of good. Am J Physiol Regul Integr Comp Physiol 2011,300(4),R804-R817","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.111.00202","volume":"61","author":"Chen J.","year":"2013","unstructured":"Chen J.; Xiao X.; Chen S.; Zhang C.; Chen J.; Yi D.; Shenoy V.; Raizada M.K.; Zhao B.; Chen Y.; Angiotensin-converting enzyme 2 priming enhances the function of endothelial progenitor cells and their therapeutic efficacy. Hypertension 2013,61(3),681-689","journal-title":"Hypertension"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1111\/bph.12770","volume":"171","author":"Jiang T.","year":"2014","unstructured":"Jiang T.; Yu J.T.; Zhu X.C.; Zhang Q.Q.; Tan M.S.; Cao L.; Wang H.F.; Lu J.; Gao Q.; Zhang Y.D.; Tan L.; Angiotensin-(1-7) induces cerebral ischaemic tolerance by promoting brain angiogenesis in a Mas\/eNOS-dependent pathway. Br J Pharmacol 2014,171(18),4222-4232","journal-title":"Br J Pharmacol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.brainres.2014.05.019","volume":"1573","author":"Xie W.","year":"2014","unstructured":"Xie W.; Zhu D.; Ji L.; Tian M.; Xu C.; Shi J.; Angiotensin-(1-7) improves cognitive function in rats with chronic cerebral hypoperfusion. Brain Res 2014,1573,44-53","journal-title":"Brain Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejphar.2014.12.007","volume":"748","author":"Wu J.","year":"2015","unstructured":"Wu J.; Zhao D.; Wu S.; Wang D.; Ang-(1-7) exerts protective role in blood-brain barrier damage by the balance of TIMP-1\/MMP-9. Eur J Pharmacol 2015,748,30-36","journal-title":"Eur J Pharmacol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bbr.2013.09.003","volume":"257","author":"Kangussu L.M.","year":"2013","unstructured":"Kangussu L.M.; Almeida-Santos A.F.; Bader M.; Alenina N.; Fontes M.A.; Santos R.A.; Aguiar D.C.; Campagnole-Santos M.J.; Angiotensin-(1-7) attenuates the anxiety and depression-like behaviors in transgenic rats with low brain angiotensinogen. Behav Brain Res 2013,257,25-30","journal-title":"Behav Brain Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1042\/CS20160116","volume":"130","author":"Almeida-Santos A.F.","year":"2016","unstructured":"Almeida-Santos A.F.; Kangussu L.M.; Moreira F.A.; Santos R.A.; Aguiar D.C.; Campagnole-Santos M.J.; Campagnole-Santos M.J.; Anxiolytic- and antidepressant-like effects of angiotensin-(1-7) in hypertensive transgenic (mRen2)27 rats. Clin Sci (Lond) 2016,130(14),1247-1255","journal-title":"Clin Sci (Lond)"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bbr.2017.05.026","volume":"331","author":"Kangussu L.M.","year":"2017","unstructured":"Kangussu L.M.; Almeida-Santos A.F.; Moreira F.A.; Fontes M.A.P.; Santos R.A.S.; Aguiar D.C.; Campagnole-Santos M.J.; Reduced anxiety-like behavior in transgenic rats with chronically overproduction of angiotensin-(1-7): Role of the Mas receptor. Behav Brain Res 2017,331,193-198","journal-title":"Behav Brain Res"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"H1057","DOI":"10.1152\/ajpheart.00433.2013","volume":"305","author":"Martins Lima A.","year":"2013","unstructured":"Martins Lima A.; Xavier C.H.; Ferreira A.J.; Raizada M.K.; Wallukat G.; Velloso E.P.; dos Santos R.A.; Fontes M.A.; Activation of angiotensin-converting enzyme 2\/angiotensin-(1-7)\/Mas axis attenuates the cardiac reactivity to acute emotional stress. Am J Physiol Heart Circ Physiol 2013,305(7),H1057-H1067","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1753944715599875","volume":"9","author":"Gironacci M.M.","year":"2015","unstructured":"Gironacci M.M.; Angiotensin-(1-7): beyond its central effects on blood pressure. Ther Adv Cardiovasc Dis 2015,9(4),209-216","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.mcn.2005.03.012","volume":"29","author":"Hellner K.","year":"2005","unstructured":"Hellner K.; Walther T.; Schubert M.; Albrecht D.; Angiotensin-(1-7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas. Mol Cell Neurosci 2005,29(3),427-435","journal-title":"Mol Cell Neurosci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.nlm.2011.10.003","volume":"97","author":"Lazaroni T.L.","year":"2012","unstructured":"Lazaroni T.L.; Raslan A.C.S.; Fontes W.R.; de Oliveira M.L.; Bader M.; Alenina N.; Moraes M.F.; Dos Santos R.A.; Pereira G.S.; Angiotensin-(1-7)\/Mas axis integrity is required for the expression of object recognition memory. Neurobiol Learn Mem 2012,97(1),113-123","journal-title":"Neurobiol Learn Mem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.phrs.2012.10.014","volume":"67","author":"Jiang T.","year":"2013","unstructured":"Jiang T.; Gao L.; Shi J.; Lu J.; Wang Y.; Zhang Y.; Angiotensin-(1-7) modulates renin-angiotensin system associated with reducing oxidative stress and attenuating neuronal apoptosis in the brain of hypertensive rats. Pharmacol Res 2013,67(1),84-93","journal-title":"Pharmacol Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1042\/CS20180189","volume":"132","author":"Gironacci M.M.","year":"2018","unstructured":"Gironacci M.M.; Vicario A.; Cerezo G.; Silva M.G.; The depressor axis of the renin-angiotensin system and brain disorders: a translational approach. Clin Sci (Lond) 2018,132(10),1021-1038","journal-title":"Clin Sci (Lond)"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1113\/expphysiol.2011.058578","volume":"96","author":"Mecca A.P.","year":"2011","unstructured":"Mecca A.P.; Regenhardt R.W.; O\u2019Connor T.E.; Joseph J.P.; Raizada M.K.; Katovich M.J.; Sumners C.; Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol 2011,96(10),1084-1096","journal-title":"Exp Physiol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/1440-1681.12137","volume":"40","author":"Sumners C.","year":"2013","unstructured":"Sumners C.; Horiuchi M.; Widdop R.E.; McCarthy C.; Unger T.; Steckelings U.M.; Protective arms of the renin-angiotensin-system in neurological disease. Clin Exp Pharmacol Physiol 2013,40(8),580-588","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11906-014-0512-2","volume":"17","author":"Bennion D.M.","year":"2015","unstructured":"Bennion D.M.; Haltigan E.; Regenhardt R.W.; Steckelings U.M.; Sumners C.; Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke. Curr Hypertens Rep 2015,17(2),3","journal-title":"Curr Hypertens Rep"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1113\/expphysiol.2013.075242","volume":"99","author":"Regenhardt R.W.","year":"2014","unstructured":"Regenhardt R.W.; Mecca A.P.; Desland F.; Ritucci-Chinni P.F.; Ludin J.A.; Greenstein D.; Banuelos C.; Bizon J.L.; Reinhard M.K.; Sumners C.; Centrally administered angiotensin-(1-7) increases the survival of stroke-prone spontaneously hypertensive rats. Exp Physiol 2014,99(2),442-453","journal-title":"Exp Physiol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.npep.2008.09.005","volume":"42","author":"Zhang Y.","year":"2008","unstructured":"Zhang Y.; Lu J.; Shi J.; Lin X.; Dong J.; Zhang S.; Liu Y.; Tong Q.; Central administration of angiotensin-(1-7) stimulates nitric oxide release and upregulates the endothelial nitric oxide synthase expression following focal cerebral ischemia\/reperfusion in rats. Neuropeptides 2008,42(5-6),593-600","journal-title":"Neuropeptides"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.neuropharm.2014.01.004","volume":"79","author":"Chen J.","year":"2014","unstructured":"Chen J.; Zhao Y.; Chen S.; Wang J.; Xiao X.; Ma, X.; Penchikala, M.; Xia, H.; Lazartigues, E.; Zhao, B.; Chen, Y. Neuronal overexpression of ACE2 protects brain from ischemia-induced damage. Neuropharmacology 2014,79,550-558","journal-title":"Neuropharmacology"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.neuropharm.2013.03.025","volume":"71","author":"Regenhardt R.W.","year":"2013","unstructured":"Regenhardt R.W.; Desland F.; Mecca A.P.; Pioquinto D.J.; Afzal A.; Mocco J.; Sumners C.; Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke. Neuropharmacology 2013,71,154-163","journal-title":"Neuropharmacology"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.npep.2013.09.002","volume":"47","author":"Lu J.","year":"2013","unstructured":"Lu J.; Jiang T.; Wu L.; Gao L.; Wang Y.; Zhou F.; Zhang S.; Zhang Y.; The expression of angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis are upregulated after acute cerebral ischemic stroke in rats. Neuropeptides 2013,47(5),289-295","journal-title":"Neuropeptides"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1038\/s41598-019-39102-8","volume":"9","author":"Arroja M.M.C.","year":"2019","unstructured":"Arroja M.M.C.; Reid E.; Roy L.A.; Vallatos A.V.; Holmes W.M.; Nicklin S.A.; Work L.M.; McCabe C.; Assessing the effects of Ang-(1-7) therapy following transient middle cerebral artery occlusion. Sci Rep 2019,9(1),3154","journal-title":"Sci Rep"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/HYPERTENSIONAHA.115.05185","volume":"66","author":"Bennion D.M.","year":"2015","unstructured":"Bennion D.M.; Haltigan E.A.; Irwin A.J.; Donnangelo L.L.; Regenhardt R.W.; Pioquinto D.J.; Purich D.L.; Sumners C.; Activation of the neuroprotective angiotensin-converting enzyme 2 in rat ischemic stroke. Hypertension 2015,66(1),141-148","journal-title":"Hypertension"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1113\/EP086957","volume":"103","author":"Bennion D.M.","year":"2018","unstructured":"Bennion D.M.; Jones C.H.; Donnangelo L.L.; Graham J.T.; Isenberg J.D.; Dang A.N.; Rodriguez V.; Sinisterra R.D.M.; Sousa F.B.; Santos R.A.S.; Sumners C.; Neuroprotection by post-stroke administration of an oral formulation of angiotensin-(1-7) in ischaemic stroke. Exp Physiol 2018,103(6),916-923","journal-title":"Exp Physiol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","volume":"11","author":"Jiang F.","year":"2014","unstructured":"Jiang F.; Yang J.; Zhang Y.; Dong M.; Wang S.; Zhang Q.; Liu F.F.; Zhang K.; Zhang C.; Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol 2014,11(7),413-426","journal-title":"Nat Rev Cardiol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","volume":"52","author":"Haschke M.","year":"2013","unstructured":"Haschke M.; Schuster M.; Poglitsch M.; Loibner H.; Salzberg M.; Bruggisser M.; Penninger J.; Kr\u00e4henb\u00fchl S.; Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 2013,52(9),783-792","journal-title":"Clin Pharmacokinet"},{"key":"ref=128","doi-asserted-by":"publisher","DOI":"10.1177\/1470320316661060","volume":"17","author":"Bennion D.M.","year":"2016","unstructured":"Bennion D.M.; Rosado C.A.; Haltigan E.A.; Regenhardt R.W.; Sumners C.; Waters M.F.; Serum activity of angiotensin converting enzyme 2 is decreased in patients with acute ischemic stroke. J Renin Angiotensin Aldosterone Syst 2016,17(3)","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neulet.2018.09.024","volume":"687","author":"Tao M.X.","year":"2018","unstructured":"Tao M.X.; Xue X.; Gao L.; Lu J.L.; Zhou J.S.; Jiang T.; Zhang Y.D.; Involvement of angiotensin-(1-7) in the neuroprotection of captopril against focal cerebral ischemia. Neurosci Lett 2018,687,16-21","journal-title":"Neurosci Lett"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.CIR.0000087339.31094.3C","volume":"108","author":"Ohkuma H.","year":"2003","unstructured":"Ohkuma H.; Suzuki S.; Fujita S.; Nakamura W.; Role of a decreased expression of the local renin-angiotensin system in the etiology of cerebral aneurysms. Circulation 2003,108(7),785-787","journal-title":"Circulation"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3892\/ijmm_00000239","volume":"24","author":"Aoki T.","year":"2009","unstructured":"Aoki T.; Nishimura M.; Kataoka H.; Ishibashi R.; Miyake T.; Takagi Y.; Morishita R.; Hashimoto N.; Role of angiotensin II type 1 receptor in cerebral aneurysm formation in rats. Int J Mol Med 2009,24(3),353-359","journal-title":"Int J Mol Med"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1227\/NEU.0b013e3182326188","volume":"70","author":"Ishibashi R.","year":"2012","unstructured":"Ishibashi R.; Aoki T.; Nishimura M.; Miyamoto S.; Imidapril inhibits cerebral aneurysm formation in an angiotensin-converting enzyme-independent and matrix metalloproteinase-9-dependent manner. Neurosurgery 2012,70(3),722-730","journal-title":"Neurosurgery"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/CCM.0b013e31822f08b9","volume":"40","author":"Timaru-Kast R.","year":"2012","unstructured":"Timaru-Kast R.; Wyschkon S.; Luh C.; Schaible E.V.; Lehmann F.; Merk P.; Werner C.; Engelhard K.; Thal S.C.; Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma. Crit Care Med 2012,40(3),935-944","journal-title":"Crit Care Med"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1038\/npp.2012.152","volume":"37","author":"Villapol S.","year":"2012","unstructured":"Villapol S.; Yaszemski A.K.; Logan T.T.; S\u00e1nchez-Lemus E.; Saavedra J.M.; Symes A.J.; Candesartan, an angiotensin II AT-receptor blocker and PPAR-\u03b3 agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. Neuropsychopharmacology 2012,37(13),2817-2829","journal-title":"Neuropsychopharmacology"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/brain\/awv172","volume":"138","author":"Villapol S.","year":"2015","unstructured":"Villapol S.; Balarezo M.G.; Affram K.; Saavedra J.M.; Symes A.J.; Neurorestoration after traumatic brain injury through angiotensin II receptor blockage. Brain 2015,138(Pt 11),3299-3315","journal-title":"Brain"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1089\/neu.2019.6376","volume":"36","author":"Janatpour Z.C.","year":"2019","unstructured":"Janatpour Z.C.; Korotcov A.; Bosomtwi A.; Dardzinski B.J.; Symes A.J.; Subcutaneous administration of angiotensin-(1-7) improves recovery after traumatic brain injury in mice. J Neurotrauma 2019,36(22),3115-3131","journal-title":"J Neurotrauma"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S1474-4422(08)70164-9","volume":"7","author":"Maas A.I.","year":"2008","unstructured":"Maas A.I.; Stocchetti N.; Bullock R.; Moderate and severe traumatic brain injury in adults. Lancet Neurol 2008,7(8),728-741","journal-title":"Lancet Neurol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6609a1","volume":"66","author":"Taylor C.A.","year":"2017","unstructured":"Taylor C.A.; Bell J.M.; Breiding M.J.; Xu L.; Traumatic brain injury-related emergency department visits, hospitalizations, and deaths - United States, 2007 and 2013. MMWR Surveill Summ 2017,66(9),1-16","journal-title":"MMWR Surveill Summ"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.bbi.2012.06.008","volume":"26","author":"Kumar A.","year":"2012","unstructured":"Kumar A.; Loane D.J.; Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. Brain Behav Immun 2012,26(8),1191-1201","journal-title":"Brain Behav Immun"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fneur.2013.00018","volume":"4","author":"Woodcock T.","year":"2013","unstructured":"Woodcock T.; Morganti-Kossmann M.C.; The role of markers of inflammation in traumatic brain injury. Front Neurol 2013,4,18","journal-title":"Front Neurol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clineuro.2016.06.009","volume":"149","author":"Nwachuku E.L.","year":"2016","unstructured":"Nwachuku E.L.; Puccio A.M.; Adeboye A.; Chang Y-F.; Kim J.; Okonkwo D.O.; Time course of cerebrospinal fluid inflammatory biomarkers and relationship to 6-month neurologic outcome in adult severe traumatic brain injury. Clin Neurol Neurosurg 2016,149,1-5","journal-title":"Clin Neurol Neurosurg"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fneur.2019.00198","volume":"10","author":"de Freitas Cardoso M.G.","year":"2019","unstructured":"de Freitas Cardoso M.G.; Faleiro R.M.; de Paula J.J.; Kummer A.; Caramelli P.; Teixeira A.L.; de Souza L.C.; Miranda A.S.; Cognitive impairment following acute mild traumatic brain injury. Front Neurol 2019,10,198","journal-title":"Front Neurol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1136\/emj.2006.045336","volume":"25","author":"Kehoe A.D.","year":"2008","unstructured":"Kehoe A.D.; Eleftheriou K.I.; Heron M.; Coats T.J.; Montgomery H.E.; Angiotensin-converting enzyme genotype may predict survival following major trauma. Emerg Med J 2008,25(11),759-761","journal-title":"Emerg Med J"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S0090-3019(00)00244-5","volume":"53","author":"Inci S.","year":"2000","unstructured":"Inci S.; Spetzler R.F.; Intracranial aneurysms and arterial hypertension: a review and hypothesis. Surg Neurol 2000,53(6),530-540","journal-title":"Surg Neurol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1161\/01.STR.0000014773.57733.3E","volume":"33","author":"Kissela B.M.","year":"2002","unstructured":"Kissela B.M.; Sauerbeck L.; Woo D.; Khoury J.; Carrozzella J.; Pancioli A.; Jauch E.; Moomaw C.J.; Shukla R.; Gebel J.; Fontaine R.; Broderick J.; Subarachnoid hemorrhage: a preventable disease with a heritable component. Stroke 2002,33(5),1321-1326","journal-title":"Stroke"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/01616412.1998.11740571","volume":"20","author":"Takenaka K.","year":"1998","unstructured":"Takenaka K.; Yamakawa H.; Sakai H.; Yoshimura S.; Murase S.; Okumura A.; Nakatani K.; Kimura T.; Nishimura Y.; Yoshimi N.; Sakai N.; Angiotensin I-converting enzyme gene polymorphism in intracranial saccular aneurysm individuals. Neurol Res 1998,20(7),607-611","journal-title":"Neurol Res"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1136\/jmg.37.7.498","volume":"37","author":"Keramatipour M.","year":"2000","unstructured":"Keramatipour M.; McConnell R.S.; Kirkpatrick P.; Tebbs S.; Furlong R.A.; Rubinsztein D.C.; The ACE I allele is associated with increased risk for ruptured intracranial aneurysms. J Med Genet 2000,37(7),498-500","journal-title":"J Med Genet"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/01.STR.0000131655.45227.f7","volume":"35","author":"Slowik A.","year":"2004","unstructured":"Slowik A.; Borratynska A.; Pera J.; Betlej M.; Dziedzic T.; Krzyszkowski T.; Czepko R.; Figlewicz D.A.; Szczudlik A.; II genotype of the angiotensin-converting enzyme gene increases the risk for subarachnoid hemorrhage from ruptured aneurysm. Stroke 2004,35(7),1594-1597","journal-title":"Stroke"}],"container-title":["Protein &amp; Peptide Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/177576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T04:17:04Z","timestamp":1596341824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/177576\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":148,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929866527666191218091823","relation":{},"ISSN":["0929-8665"],"issn-type":[{"value":"0929-8665","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}